Mads Daugaard

President på RAKOVINA THERAPEUTICS INC.

Finance

Consumer Services

Commercial Services

Profil

Mads Daugaard is the founder of VarCT Diagnostics ApS, founded in 2017, and Var2 Pharmaceutical, founded in 2012, where the title held is Chairman.
Current jobs include Chairman at Oncomal ApS, Associate Professor at the University of British Columbia, and President & Chief Scientific Officer at Rakovina Therapeutics, Inc. since 2021.
Former job includes Head-Molecular Pathology & Cell Imaging Unit at The Vancouver Prostate Centre.

Aktiva positioner av Mads Daugaard

Företag	Position	Start
RAKOVINA THERAPEUTICS INC.	President	2021-01-01
University of British Columbia University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University	Företagsledare/Principal	-
Var2 Pharmaceutical	Grundare	2012-01-01
VarCT Diagnostics ApS VarCT Diagnostics ApS VarCT Diagnostics ApS specializes in developing in vitro diagnostic assays for cancer detection and monitoring, focusing on the oncofetal chondroitin sulfate (ofcs) biomarker, which is re-expressed in most cancers but largely absent from healthy tissues except the placenta. The private company is based in Copenhagen, Denmark. The Danish company utilizes recombinant var2csa protein and proprietary high-affinity antibodies called vartumabs to detect ofcs with high sensitivity and specificity. The company's assays support early cancer detection, residual disease monitoring, and multi-cancer screening, including colorectal and bladder cancers, and they are developing immunohistochemistry companion diagnostics for tumor biopsies. VarCT Diagnostics is also advancing therapeutic applications using vartumabs-based platforms and plans a phase 0 microdosing clinical trial in 2024. The company maintains strategic collaborations with academic and industry partners internationally. The company was founded by Mads Daugaard.	Grundare	2017-01-01
Oncomal ApS Oncomal ApS Financial ConglomeratesFinance Functions as a financial holding company	Ordförande	-

Alla aktiva positioner av Mads Daugaard

Tidigare kända positioner av Mads Daugaard

Företag	Position	Slut
The Vancouver Prostate Centre The Vancouver Prostate Centre Miscellaneous Commercial ServicesCommercial Services Provides prostate cancer research, treatment, and education services	Företagsledare/Principal	-

Se detaljerna i Mads Daugaards erfarenhet

Erfarenheter
Innehade positioner

Aktiva

Inaktiva

Börsnoterade företag

Privata företag

Se detaljerna i Mads Daugaards erfarenhet

Relationer

Första gradens relationer

Företag kopplade till första graden

Man

Kvinna

Styrelseledamöter

Chefer

Se det personliga nätverket

Kopplade företag

Privata företag	6
University of British Columbia University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
The Vancouver Prostate Centre The Vancouver Prostate Centre Miscellaneous Commercial ServicesCommercial Services Provides prostate cancer research, treatment, and education services	Commercial Services
Rakovina Therapeutics, Inc. Rakovina Therapeutics, Inc. Financial ConglomeratesFinance Develops oncology therapeutics	Finance
Var2 Pharmaceutical
Oncomal ApS Oncomal ApS Financial ConglomeratesFinance Functions as a financial holding company	Finance
VarCT Diagnostics ApS VarCT Diagnostics ApS VarCT Diagnostics ApS specializes in developing in vitro diagnostic assays for cancer detection and monitoring, focusing on the oncofetal chondroitin sulfate (ofcs) biomarker, which is re-expressed in most cancers but largely absent from healthy tissues except the placenta. The private company is based in Copenhagen, Denmark. The Danish company utilizes recombinant var2csa protein and proprietary high-affinity antibodies called vartumabs to detect ofcs with high sensitivity and specificity. The company's assays support early cancer detection, residual disease monitoring, and multi-cancer screening, including colorectal and bladder cancers, and they are developing immunohistochemistry companion diagnostics for tumor biopsies. VarCT Diagnostics is also advancing therapeutic applications using vartumabs-based platforms and plans a phase 0 microdosing clinical trial in 2024. The company maintains strategic collaborations with academic and industry partners internationally. The company was founded by Mads Daugaard.